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SUMMARY
Trypanosoma brucei is the causative agent of African sleeping sickness in humans and one of several pathogens that cause the
related veterinary disease Nagana. A complex co-evolution has occurred between these parasites and primates that led to the
emergence of trypanosome-speciﬁc defences and counter-measures. The ﬁrst line of defence in humans and several other
catarrhine primates is the trypanolytic protein apolipoprotein-L1 (APOL1) found within two serum protein complexes,
trypanosome lytic factor 1 and 2 (TLF-1 and TLF-2). Two sub-species of T. brucei have evolved speciﬁc mechanisms to
overcome this innate resistance, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense. In T. b. rhodesiense, the
presence of the serum resistance associated (SRA) gene, a truncated variable surface glycoprotein (VSG), is suﬃcient to
confer resistance to lysis. The resistance mechanism of T. b. gambiense is more complex, involving multiple components:
reduction in binding aﬃnity of a receptor for TLF, increased cysteine protease activity and the presence of the truncated
VSG, T. b. gambiense-speciﬁc glycoprotein (TgsGP). In a striking example of co-evolution, evidence is emerging that
primates are responding to challenge by T. b. gambiense and T. b. rhodesiense, with several populations of humans and
primates displaying resistance to infection by these two sub-species.
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INTRODUCTION
Trypanosoma brucei is the causative agent of African
sleeping sickness in humans and one of several species
that causes the related veterinary disease Nagana.
Both diseases have a wide distribution across sub-
Saharan Africa and aﬀect some of the poorest areas
of the world. Trypanosoma brucei is traditionally
segregated into three morphologically identical sub-
species based on host, geography and pathology,
although the polyphyletic nature of the three sub-
species and evidence for mating between them makes
grouping them as such problematic. Trypanosoma
brucei brucei is limited to domestic and wild animals
throughout sub-Saharan Africa and is non-infective
to humans (and some primates) due to sensitivity
to trypanosome lytic factors (TLF) found in its
serum (Seed and Sechelski, 1990; Lugli et al. 2004).
Trypanosoma brucei gambiense and Trypanosoma
brucei rhodesiense are human infective sub-species,
named due to their relative geographic locations.
Trypanosoma b. gambiense is found in Western and
Central sub-Saharan African and causes a chronic
infection that can persist for many years before
symptoms appear (Gibson, 1986). It appears to be
largely a disease limited to humans, although some
animal reservoirs have been described (Gibson et al.
1978; Mehlitz, 1979; Felgner et al. 1981; Mehlitz
et al. 1981, 1982; Zillmann et al. 1984). Trypanosoma
b. rhodesiense is found in a limited but expanding area
of Eastern sub-Saharan Africa, and there is a large
potential animal reservoir in wild and domesticated
animals (Welburn et al. 2001; Fèvre et al. 2001, 2005;
Odiit et al. 2005). This sub-species causes a
more acute form of the disease than T. b. gambiense
(Gibson, 2002), although T. b. gambiense is by far
the more prevalent human-infective sub-species and
is responsible for more than 97% of human cases
(World Health Organization, 2006; Simarro et al.
2011). The evolution of TLF in primates and the
adaptations ofT. brucei sub-species to resist lysis rep-
resent an excellent example of the co-evolutionary
arms race between host and parasite.
HUMAN RESISTANCE TO TRYPANOSOME
INFECTION
It has been known for more than a century that a
component found in the serum of several primates,
including humans, is toxic to trypanosomes (Fig. 1)
(Laveran and Mesnil, 1912). After exposure to
human serum, most trypanosomes are rapidly lysed
with a deﬁned morphology (Pays et al. 2006). Lysis is
* Corresponding author: Wellcome Centre for Molecular
Parasitology, College of Medical, Veterinary and Life
Sciences, University of Glasgow, 464 Bearsden Road,
Glasgow G61 1QH, UK. E-mail: paul.capewell@glasgow.
ac.uk
1SUPPLEMENT ARTICLE
Parasitology, Page 1 of 12. © Cambridge University Press 2014. The online version of this article is published within an Open Access
environment subject to the conditions of the Creative Commons Attribution licence http://creativecommons.org/licenses/by/3.0/
doi:10.1017/S0031182014000602
preceded by a characteristic swelling of the lysosome,
suggesting that this organelle is intimately involved
in the process. Fractionation of human serum iden-
tiﬁed a speciﬁc high-density lipoprotein (HDL)
particle approximately 500 kDa in size that was
able to lyse trypanosomes (Rifkin, 1978a,b; Hajduk
et al. 1989). This particle was originally termed the
TLF but later renamed TLF-1 after the discovery of
a second particle, a high molecular weight serum
protein-binding complex related to TLF-1 that was
consequently namedTLF-2 (Raper et al. 1996). Both
TLF-1 and TLF-2 contain the same protein com-
plement: apolipoprotein A1 (APOA1), apolipopro-
tein L1 (APOL1) and haptoglobin-related protein
(HPR), although TLF-1 is predominantly composed
of lipid while TLF-2 is lipid poor (Raper et al. 2001).
Despite this, TLF-2 is a much larger particle than
TLF-1 due to being bound to several IgMmolecules
(Tomlinson et al. 1995; Raper et al. 1996). Consider-
able eﬀort and much debate has focused on deter-
mining the trypanolytic component of TLF, largely
focusing on TLF-1 as a result of the diﬃculty of
purifying active TLF-2 ex vivo (Tomlinson et al.
1995; Raper et al. 1996). Investigation has centred on
the two primate-speciﬁc proteins found in TLF, i.e.
HPR and APOL1, both of which are the result of
tandem gene duplication events during primate
evolution. HPR is a haemoglobin binding protein
with high sequence similarity to the haem scavenger
protein haptoglobin (HP). Found within the same
HDL complex as HPR, APOL1 is a lipid-binding
protein that possesses both a secretory signal peptide
and a Bcl-2 homology 3 (BH3) domain (Duchateau
et al. 1997; Wan et al. 2008; Zhaorigetu et al. 2008).
The BH3 domain is an important pro-apoptotic
regulator of autophagy in many cell types (Lutz,
2000) and APOL1 itself appears to be able to induce
autophagy if over-expressed in cell lines, indicating it
may have a role in vertebrate controlled cell death
(Zhaorigetu et al. 2008). APOL1 mutations are also
associatedwith various pathologies, including schizo-
phrenia and chronic kidney diseases (Mimmack et al.
2002; Genovese et al. 2010; Tzur et al. 2010).
While there has been some controversy concerning
the roles of these two proteins with regards trypano-
some lysis, the current consensus is that both proteins
are necessary for optimal lysis and that HPR and
APOL1 have complementary roles (Vanhollebeke
et al. 2007; Widener et al. 2007). Although it has also
been shown to have some trypanosome-speciﬁc
toxicity itself (Harrington et al. 2010), possibly due
to the un-cleaved signal peptide, which can aﬀect
membrane ﬂuidity (Harrington et al. 2010), HPR
acts primarily as a ligand. Similar to its haptoglobin
ancestor, HPR binds haemoglobin and thus facil-
itates uptake of TLF-1 via a parasite haptoglobin-
haemoglobin receptor (HpHbR) (Vanhollebeke et al.
2008; Vanhollebeke and Pays, 2010). This strategy
likely evolved to take advantage of the fact that
trypanosomes are haem auxotrophs (Korený et al.
2010). After being endocytosed (Hager et al. 1994),
the TLF-1 particle is traﬃcked to the lysosomewhere
APOL1 is released. The hairpin structure of APOL1
is normally conﬁgured closed at neutral pH, however,
the low pH of the lysosome disperses the salt bridges
which stabilize the hairpin ‘hinge’, resulting in a
conformational change (Vanhollebeke and Pays,
2006). This reveals a membrane-addressing domain
and the BH3 pore-forming domain (Vanhollebeke
and Pays, 2006). With both of these domains ex-
posed, APOL1 embeds in the lysosomal membrane,
forming anionic pores and thus perturbing the
osmotic balance of the organelle. This leads to lysis
of the parasite, either by simple mechanical dis-
ruption due to swelling of the organelle or the
leakage of digestive enzymes into the main cell body
(Vanhamme et al. 2003; Pays et al. 2006;
Vanhollebeke and Pays, 2010). As both HPR and
Fig. 1. APOL gene cluster of various primate species. The complement of APOL genes and pseudogenes in several
primate genera. The proposed genomic arrangement for each genus is shown, with pseudogenes indicated by ψ and *.
The potential for the species’ serum to lyse T. brucei is also indicated (adapted from Smith and Malik, 2009).
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APOL1 are found in TLF-2, it is likely that the lysis
method for this particle involves both of these
proteins, although the method of entry for TLF-2
only partially involves the HpHbR receptor (Bullard
et al. 2012). Themechanism by which the majority of
TLF-2 is bound and internalized by the parasite is
currently unknown, but may involve weak interac-
tions between IgM and the VSG coat of the parasite
or a second receptor for TLF that has been described
(Drain et al. 2001; Green et al. 2002; Vanhollebeke
and Pays, 2010). The second trypanosome receptor
for TLF is unidentiﬁed but was ﬁrst described from
low temperature binding assays showing TLF-1 is
internalized by both a high-aﬃnity low copy number
receptor (now known to be HpHbR) and a second
low-aﬃnity, high copy number receptor (Drain et al.
2001). The putative second receptor was further
investigated using HDL competition, binding and
uptake assays (Green et al. 2002) and shown to act as a
general lipoprotein scavenger which binds multiple
classes of lipoprotein, including HDL, LDL, oxi-
dized LDL and TLF.
Primates have likely evolved this highly eﬀective
innate immunity based on APOL1 because trypano-
somes have escaped the eﬀects of the adaptive im-
mune response due to antigenic variation (Barry and
McCulloch, 2001; Pays et al. 2001). Trypanosomes
are covered in a highly immunogenic, dense, variable
surface glycoprotein coat, which is rapidly turned
over with the parasite membrane and frequently
switched to a diﬀerent VSG, rendering antibody-
based immunity ineﬀective. The high turnover of the
parasite’s surface membrane requires a large amount
of lipid, however, trypanosomes are lipid auxotrophs
and so obtain their lipids in the form of HDL from
their host (Green et al. 2002). The packaging of
APOL1 into HDL exploits the parasite’s require-
ment for this essential nutrient to deliver the highly
toxic APOL1 molecule.
Dating the emergence of trypanolytic APOL1
in primates is challenging as the APOL gene cluster
has undergone numerous expansion, duplication and
loss events during primate evolution (Fig. 1) (Smith
and Malik, 2009), although it must precede the time
when the hominidae and cercopithecidae primate line-
ages diverged as both possess lytic APOL1 (approxi-
mately 20 mya) (Seed and Sechelski, 1990; Lugli
et al. 2004). The addition of a secretory signal peptide
to APOL1 appears to be a unique key factor allow-
ing its use as a protective element against trypano-
somes, as all other APOL proteins are intracellular
(Vanhollebeke and Pays, 2006). The signal peptide
appears to have originated due to a gain of function
mutation after the divergence of APOL1 and APOL2
(Smith and Malik, 2009). Although the APOL1
defensive strategy works successfully against most
species of African trypanosome, two human infective
trypanosome sub-species have evolved to counter
the innate defence provided by primate APOL1.
Interestingly, both sub-species utilize a truncated
VSG as an essential component of their resistance
mechanisms. As several other genes also derive from
VSGs, including the transferrin receptor ESAG6/
ESAG7, it would appear that the huge VSG
repertoire of these parasites provides a powerful
resource that can be utilized by trypanosomes to
quickly evolve to infect new hosts and overcome
novel challenges (Jackson et al. 2013).
TRYPANOSOMA B. RHODESIENSE RESISTANCE
TO TLF AND APOL1
Work to elucidate how the human infective sub-
species of T. brucei overcame APOL1-mediated lysis
initially focused on T. b. rhodesiense. A deﬁning
characteristic of human serum resistance within this
sub-species is its variable phenotype. The serum
resistance phenotype can vary during animal passage,
with individual passages exhibiting the phenotype
to diﬀering degrees (Targett and Wilson, 1973;
Willett and Fairbairn, 1955). It was noted that
the expression of the resistance phenotype closely
correlates with changes to the expressed VSG (van
Meirvenne et al. 1976). This implicated an express-
ion site associated gene (ESAG) being responsible
for resistance (Fig. 2) (Rifkin et al. 1994). Com-
parison of isogenic serum-susceptible and serum-
resistantT. b. rhodesiense lines provided an invaluable
research tool and by comparing mRNA, a VSG-like
gene transcript associated with resistance was iden-
tiﬁed (De Greef et al. 1989; De Greef et al. 1992).
Both resistant and sensitive T. b. rhodesiense possess
the serum resistance associated (SRA) gene, but
only resistant lines actively transcribe it. Conclusive
proof that human serum resistance inT. b. rhodesiense
was due to this single gene was shown when trans-
genic T. b. brucei expressing SRA gained resistance
to lysis by human serum (Xong et al. 1998).
Anecdotally, this result was solidiﬁed by accidental
infection of a human with this T. b. brucei–SRA
strain (Gibson, 2005), demonstrating that the SRA
gene alone is suﬃcient to confer human serum
resistance.
SRA has been shown to be present in nearly all
T. b. rhodesiense lines (Gibson et al. 2002) although
this is a circular argument, i.e. the presence of SRA
is diagnostic of T. b. rhodesiense, so T. b. rhodesiense
must always possess SRA. Structurally, the SRA
gene appears to be a truncated VSG with a large
deletion of a region in the centre of the sequence
encoding the N-terminal domain (De Greef et al.
1992; DeGreef and Hamers, 1994; Xong et al. 1998).
SRA is present on the cell surface (Milner and
Hajduk, 1999), where it is internalized in the ﬂagellar
pocket during cell surface protein turnover, leading
to SRA presence in the endosomes and lysosome
(Vanhamme et al. 2003; Oli et al. 2006; Shiﬂett et al.
2007). This is similar to the location of APOL1 in the
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endosomal pathway before lysis. The deletion of
126 amino acids in SRA removes two surface loops
normally present in a VSG protein, exposing the
internal α-helices (Fig. 2) (Campillo and Carrington,
2003). Based on modelled tertiary structure, it was
proposed that the deletion resulted in human serum
resistance by allowing an inter-chelating interaction
between the exposed N-terminal helices of SRA
and the C-terminal helical section of APOL1 after
the protein undergoes conformational change in the
acidic environment of the lysosome (Vanhamme et al.
2003; Vanhamme and Pays, 2004).
SRA is conserved at the nucleotide level in the
T. b. rhodesiense population, with less than 3% se-
quence variation between strains (Gibson et al. 2002).
The polymorphisms present in the SRA gene, which
can be diﬀerentiated by allele-speciﬁc PCR (Gibson
et al. 2002), divide T. b. rhodesiense into two groups,
‘Northern’ and ‘Southern’, broadly along geographi-
cal lines (Gibson et al. 2002; MacLean et al. 2004,
Balmer et al. 2001). This geographical segregation
of SRA variants associates closely with the mol-
ecular and clinical disease proﬁles that have also
detected delineation betweenNorthern and Southern
T. b. rhodesiense strains (Gibson et al. 1980; Hide
et al. 1991; MacLeod et al. 2000; MacLean et al.
2004).
The conservation of the SRA gene sequence
combined with population analyses, which have
highlighted the close genetic relationship between
sympatric T. b. rhodesiense and T. b. brucei strains
(Hide et al. 1994; MacLeod et al. 2000), indicate that
although the formation of SRA is likely to have
been the result of a single gene recombination
event (Campillo and Carrington, 2003), human
infectivity has spread in East Africa by genetic
exchange of the SRA gene into genetically diverse
T. b. brucei backgrounds, thereby creating new strains
of T. b. rhodesiense (Gibson et al. 2002; Duﬀy et al.
2013). This potential for genetic exchange between
T. b. brucei andT. b. rhodesiense, alongside the demon-
stration that expression of the SRA gene is all that is
necessary for human serum resistance (Xong et al.
1998) has implications for the evolution of the
disease, as the SRA gene may be transferred onto
new genetic backgrounds resulting in genotypes with
altered pathogenicity.
The discovery of SRA has led to advancements in
diagnosis and suggested preventative action to com-
bat sleeping sickness caused byT. b. rhodesiense.With
the advent of speciﬁc PCR markers for SRA,
trypanosomes with the potential to infect humans
can be identiﬁed unambiguously without the need for
laborious human serum resistance assays such as the
BIIT (Welburn et al. 2001; Gibson et al. 2002;
Radwanska et al. 2002). By providing a robust and
speciﬁc single gene assay, requiring as little as a single
parasite in starting material, SRA-PCR has proved
revolutionary in understanding the role of wildlife
and livestock in the epidemiology of the disease. For
example, traditional microscopy techniques and
HSR assays estimated the number of domestic cattle
carrying human infective T. b. rhodesiense to be
approximately 1%. PCR analysis has indicated that
instead this value is closer to 18% (Welburn et al.
2001). Although the discovery of SRA has been a
major boon to the understanding of T. b. rhodesiense
genetics and biology, this gene is not present in the
dominant human infective trypanosome sub-species,
T. b. gambiense. Additionally, several strains have
been described from T. b. rhodesiense foci that are
human serum resistant but for which the SRA gene
cannot be ampliﬁed by PCR (De Greef et al. 1992;
Enyaru et al. 2006). Whether this is due to divergent
SRA sequence in these strains or a novel resistance
mechanism is unknown.
TRYPANOSOMA B. GAMBIENSE RESISTANCE TO
TLF AND APOL1
Investigating the human serum resistance phenotype
ofT. b. gambiense has been hampered by the diﬃculty
in working with the sub-species in a laboratory
setting. Trypanosoma b. gambiense typically grows to
very low parasitaemia and there have been immense
diﬃculties in adapting it to in vitro or in vivomodels.
Fig. 2. Human serum resistance of T. b. rhodesiense. (Upper) Schematic diagram of a typical trypanosome expression
site and the SRA expression of T. b. rhodesiense (adapted from Gibson, 2005). (Lower) Diagram of the typical domains
of a VSG and the approximate location of the 378 bp deletion in the SRA gene (adapted from Campillo and Carrington,
2003).
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However, recent advances have allowed the gener-
ation of laboratory adapted lines and successful trans-
fections have now been achieved (Baltz et al. 2009;
Capewell et al. 2013; Uzureau et al. 2013). It is now
possible to unravel the intricacies of the resistance
phenotype of T. b. gambiense. An important ﬁrst step
was the observation that T. b. gambiense does not ap-
pear to internalize ﬂuorescently tagged TLF-1 (Kieft
et al. 2010; Capewell et al. 2011). This suggested that
avoidance of TLF-1 is a feature of human serum
resistance in T. b. gambiense. Several polymorphisms
were identiﬁed in the HpHbR gene unique to
T. b. gambiense relative to other T. brucei that aﬀected
TLF-1 uptake (Kieft et al. 2010). Subsequent
research has conﬁrmed that a single polymorphism
reduced the binding aﬃnity of HpHbR for its ligand
20-fold (DeJesus et al. 2013; Higgins et al. 2013).
This polymorphism appears to be conserved across
several T. b. gambiense foci (Symula et al. 2012).
Avoidance of TLF-1 therefore appears to be a con-
served trait in T. b. gambiense. Over-expression of a
functional T. b. brucei HpHbR in T. b. gambiense
results in normal TLF-1 uptake and restricted
growth (Capewell et al. 2013). Incubating wild-type
T. b. gambiense with serum containing high levels
of TLF-1 also appears to result in the serum re-
sistance mechanism of T. b. gambiense becoming
overwhelmed (Uzureau et al. 2013). While the
reduced expression and activity of HpHbR pro-
vide a plausible explanation for how T. b. gambiense
avoids lysis by TLF-1, it does not explain how
T. b. gambiense is able to avoid uptake and consequent
lysis by TLF-2. This lytic particle is only partially
internalized via HpHbR (Bullard et al. 2012).
Additionally,T. b. gambiense exposed to recombinant
APOL1internalizedbynon-speciﬁcﬂuidphase endo-
cytosis are still resistant despite observable uptake
and traﬃcking of the lytic protein to the lysosome
(Capewell et al. 2011).
In an eﬀort to discover the factor that confers
resistance to TLF-2 and APOL1, the genomes of
bothT. b. brucei andT. b. gambiensewere interrogated
(Berriman, 2005; Jackson et al. 2010). To date,
only one gene has been found to be unique to
T. b. gambiense, the gene encoding the T. gambiense-
speciﬁc glycoprotein (TgsGP) (Berberof et al. 2001).
This gene was found while attempting to discover
truncated VSGs similar to SRA in T. b. gambiense.
Unlike SRA, TgsGP is not found in an expression
site but is rather transcribed from a core chromoso-
mal locus. This region was formed by an inversion
event that disrupted part of chromosome 2 that
allowed an ordinarily silent region containing VSGs
to be transcribed (Fig. 3) (Berberof et al. 2001;
Fig. 3. Human serum resistance of T. b. gambiense. (Upper) Model of the chromosomal inversion on chromosome 2 that
allowed the silent region containing the progenitor of TgsGP to be constitutively transcribed and undergo selection. The
inversion is present on one homologue of chromosome 2 and is conserved across all T. b. gambiense (adapted from
Berberof et al. 2001; Felu et al. 2007). (Lower) Diagram of the typical domains of a VSG and the approximate location
of the C-terminal deletion in TgsGP (adapted from (Gibson et al. 2010)).
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Felu et al. 2007). This inversion event is ancestral and
speciﬁc toT. b. gambiense (Felu et al. 2007). AVSG or
VSG pseudogene close to an AUT1 fragment cleaved
by the inversion has since evolved into the TgsGP
gene. TgsGP appears to be highly conserved across
several T. b. gambiense disease foci so is likely to have
evolved only once (Gibson et al. 2010). It diﬀers from
other VSGs in that it does not possess the conserved
VSGC-terminal domain and possesses a GPI anchor
related to that of ESAG6s (Fig. 3) (Felu et al. 2007).
It is closely related to the VSG Tb10.v4·0178,
sharing more than 80% genetic similarity, indicating
a possible ancestral VSG (Gibson et al. 2010).
Initially TgsGP was thought unlikely to be involved
in human serum resistance as ectopic expression
of the gene in T. b. brucei did not confer resistance
(Berberof et al. 2001). However, this does not take
into account other factors that may be present in
T. b. gambiense and absent in T. b. brucei that are
necessary for TgsGP to function. When the TgsGP
gene was deleted from the genome of T. b. gambiense,
parasites became sensitive to both human serum and
APOL1 (Capewell et al. 2013; Uzureau et al. 2013),
although the parasites were still resistant to TLF-1.
Removal of the TgsGP gene from T. b. gambiense
parasites ectopically expressing a functional
T. b. brucei HpHbR resulted in the parasites be-
coming sensitive to TLF-1 (Capewell et al. 2013;
Uzureau et al. 2013). How TgsGP confers resistance
is still unknown as there is no direct interaction
between APOL1 and TgsGP despite both being
found in similar endosomal compartments (Uzureau
et al. 2013). Serial modiﬁcation and ectopic ex-
pression ofTgsGP indicated the presence of a speciﬁc
Β-sheet structure within the protein that is essential
for TgsGP to function. It was hypothesized that this
Β-sheet structure interacts with and strengthens the
parasite’s internal membranes to allow them to resist
the pore-forming activity of APOL1. Support for
this hypothesis is based on the observation that
recombinant TgsGP and derived peptides integrate
with artiﬁcial lipid bilayers and can aﬀect lateral ﬂow
of the parasite surface membrane (Uzureau et al.
2013). This suggests that membrane ﬂuidity is
diﬀerent in T. b. gambiense (that contains TgsGP)
compared with T. b. brucei and suggests a causal
relationship with the human serum resistance pheno-
type. This is indeed a tempting hypothesis, although
a direct relationship between the observation
and human infectivity has not been shown. Re-
combinant TgsGP and related peptides have a
negligible eﬀect on human serum resistance when
incubated with T. b. brucei. This fact, coupled to the
observations that ectopic expression of TgsGP
in T. b. brucei does not confer resistance and that
TgsGP knockout T. b. gambiense still displays a
markedly higher resistance to human serum than
other T. b. brucei, suggests other factors may be
present in T. b. gambiense that function in concert
with TgsGP (Berberof et al. 2001; Capewell et al.
2011; Uzureau et al. 2013).
One possible candidate for involvement is the
cysteine protease protein family. These enzymes are
heavily involved in degradation of host proteins, with
several found in the endosomal pathway and lyso-
some. It has been demonstrated that cysteine protease
inhibitors aﬀect the ability ofT. b. brucei to resist lysis
by human serum, perhaps by aﬀecting degradation of
the TLF particles or APOL1 itself (Bishop et al.
2001). General inhibition of cysteine peptidase in
T. b. gambiense strains without TgsGP reduced their
capacity to resist human serum and APOL1 to a level
approximately equivalent to T. b. brucei (Uzureau
et al. 2013). RNAi and knockouts of ICP (inhibitor of
cysteine peptidase) cause a general increase in
cysteine protease expression in T. b. brucei and also
raise human serum resistance, suggesting that these
proteases could be a factor (Uzureau et al. 2013).
However, an experiment that over-expresses cysteine
proteases in a T. b. brucei with ectopic TgsGP
expression has not been undertaken. This would
conﬁrm if high cysteine protease activity is indeed the
missing factor necessary for TgsGP to function in
T. b. brucei. While higher expression of cysteine
proteases in T. b. gambiense may be the eﬀector that
leads to greater human serum resistance, it was also
noted that the pH of the endocytic compartment of
T. b. gambiense is slightly lower than that of
T. b. brucei (Uzureau et al. 2013). This may increase
the degradation of APOL1 and elicit a protective
eﬀect. Several T. brucei cysteine proteases, particu-
larly cathepsins, are more active at low pH (O’Brien
et al. 2008). Again, this hypothesis has not been
tested and is at present conjecture.
Taken together, it would appear that the resistance
mechanism ofT. b. gambiense involves several factors:
(1) reduction of lytic particle uptake by reducing
expression and binding aﬃnity of the HpHb recep-
tor, (2) expression of TgsGP possibly aﬀecting
membrane ﬂuidity and resistance to APOL1 disrup-
tion and (3) increased amounts of cysteine proteases
that aid degradation of APOL1.
EVOLVING PRIMATE RESISTANCE TO
T. B . RHODESIENSE AND T. B . GAMBIENSE
Although the mechanisms for how primates resist
trypanosome infection and how some trypanosomes
have overcome this resistance are becoming clearer,
the evolutionary arms race between primates and
trypanosomes continues. It is becoming apparent
that mechanisms to combat infection of both
T. b. rhodesiense and T. b. gambiense in primates
have evolved and are continuing to evolve. Although
trypanolytic APOL1 evolved in the ancestors of
catarrhine primates, it appears to have diverged into
two distinct lineages that exhibit diﬀering eﬃcacies of
trypanosome lysis. APOL1 from the hominidae
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lineage (gorillas and humans) is eﬀective against
most trypanosomes (Seed and Sechelski, 1990;
Lugli et al. 2004), except T. b. rhodesiense and
T. b. gambiensewhile APOL1 from the cercopithecidae
lineage (baboons and macaques) is also able to lyse
T. b. rhodesiense (Seed and Sechelski, 1990; Kageruka
et al. 1991; Thomson et al. 2009). Cercopithecidae
lineage APOL1 is able to lyseT. b. rhodesiense due to a
modiﬁcation of the SRA interacting domain of
APOL1 at the C-terminus of the protein (Fig. 4),
which disrupts SRAbinding after APOL1has under-
gone conformational change (Lecordier et al. 2009;
Thomson et al. 2009). Recombinant protein created
by deleting this domain from human APOL1 is also
able to lyse T. b. rhodesiense, suggesting that evolving
a modiﬁcation to this region of APOL1 would render
humans resistant to T. b. rhodesiense (Lecordier et al.
2009). There is preliminary evidence that this may
have occurred with the identiﬁcation of selection for
two speciﬁc APOL1 alleles (G1 and G2) in African
Americans with ancestry in sub-Saharan Africa
(Genovese et al. 2010). Both the G1 and G2 alleles
of APOL1 show modiﬁcation of the SRA binding
region (Fig. 4) and recombinant versions of these
alleles, particularly G2, are able to reduce the growth
of T. b. rhodesiense parasites in vitro (Genovese et al.
2010). However, presence of these alleles also cor-
relates with increased incidence of kidney disease,
particularly in individuals homozygous for either
allele (Freedman et al. 2010; Genovese et al.
2010; Tzur et al. 2010). The maintenance of a trait
that is beneﬁcial to heterozygotes but deleterious
to homozygotes parallels the well-described
co-evolutionary interplay between sickle-cell anae-
mia andPlasmodium (Williams et al. 2005). However,
to date, no case-controlled study using natural
populations has been undertaken to test the hypoth-
esis that G1/G2 selection is due to pressure from
trypanosomes. A study examining APOL1 selection
across Africa found extremely low prevalence for G2,
and G1 was only present in a population not exposed
to T. b. rhodesiense (Ko et al. 2013). They did,
however, ﬁnd a much higher number of non-
synonymous mutations in the SRA binding domain
of APOL1 than would be expected by chance.
While less well studied than T. b. rhodesiense, it is
also possible that there are primates or human popu-
lations that have evolved APOL1 alleles that protect
against T. b. gambiense. The Bambuti people of the
Mbomo region in the Democratic Republic of the
Congo have long been believed to be less susceptible
to African sleeping sickness (Frezil, 1983), although
no controlled study has been performed to test this
assumption or investigate their APOL1 alleles. It is
also becoming increasingly apparent that infection by
T. b. gambiense is not always fatal with the recent
identiﬁcation of asymptomatic and self-cure cases
from Côte d’Ivoire (Ilboudo et al. 2012; Jamonneau
et al. 2012). The APOL1 sequences from these in-
dividuals have not been assessed, although a recent
study assessing APOL1 selection across Africa has
identiﬁed an allele termed G3 that is under selection
in the Fulani people of Cameroon, a region aﬀected
byT. b. gambienseAfrican sleeping sickness (Ko et al.
2013). This particular allele diﬀers from the G1/G2
variants that have a mutation in the SRA interacting
domain and instead possesses a mutation in the
membrane-addressing domain of APOL1 (Fig. 4). It
is, as yet, unknown if this variant is protective against
T. b. gambiense. Looking outside human populations
and to the Cercopithecidae lineage of APOL1, the
baboon species Papio papio appears to only be tran-
siently infected by T. b. gambiense. This species
range overlaps with that of T. b. gambiense, while
the ranges of other Papio species that are not resistant
to the disease do not overlap (Kageruka et al. 1991;
Lecordier et al. 2009; Thomson et al. 2009). It is
possible that this species of baboon has evolved an
APOL1 variant that is able to lyse T. b. gambiense
due to exposure to the disease. Finally, while the
majority of eﬀort has primarily concentrated on
ﬁnding APOL1 variants toxic to human infective
trypanosomes, other proteins may also contribute.
For example, speciﬁc alleles of IL-6 and IL-10 have
been associated with resistance to T. b. gambiense in
humans (Courtin et al. 2006, 2007; Garcia et al.
2006). A recent study has also reported evidence that
alleles containing a duplication of the parasite re-
ceptor ligand,HPR, are present at high frequency in
Central and West African populations endemic to
T. b. gambiense, relative to the global distribution.
However, whether such duplication oﬀers any
Fig. 4. APOL1 variants. Several variants of APOL1
show diﬀering lysis eﬃcacy against trypanosomes. Wild-
type human APOL1 can lyse T. congolense, T. vivax and
T. b. brucei. Baboon APOL1 possesses two consecutive
lysines rather than asparagines in the SRA-interacting
domain of APOL1 (black lines). This reduces the binding
aﬃnity of SRA to APOL1, allowing the baboon protein
to lyse T. b. rhodesiense. G1/G2 human alleles are under
selection in populations of African descent and also
possess modiﬁcations to the SRA-interacting domain of
APOL1 (black lines, white box). Like baboon APOL1,
these alleles demonstrate eﬃcacy against T. b. rhodesiense.
The G3 allele is under selection in populations exposed to
T. b. gambiense but eﬃcacy of this allele against
trypanosome sub-species has not been assessed. Unlike
G1/G2, G3 mutations lie within the pore-forming and
membrane-addressing domains of APOL1 (black lines).
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protective eﬀect against T. b. gambiense sleeping
sickness has not yet been experimentally tested
(Hardwick et al. 2014). There was no signiﬁcant
link between HPR duplication and the presentation
of sleeping sickness in children in aﬀected areas,
although this may be due to the low power of the
study. To discover other possible factors involved in
genetic susceptibility to African sleeping sickness,
large-scale genome-wide association studies should
be undertaken.
DISCUSSION AND FUTURE DIRECTIONS
The co-evolutionary arms race between trypano-
somes and primates is a fascinating case study in
parasite and host interactions. As the mammalian
adaptive immune system is rendered ineﬀective by
the trypanosomes’ antigenic variation strategy, pri-
mates have evolved speciﬁc countermeasures to
target trypanosomes utilizing the trypanolytic pro-
tein APOL1 bound to HDL (Summary: Fig. 5).
Fig. 5. Summary of the co-evolutionary arms race between African trypanosomes and the primate host. Humans are
protected from infection from the majority of Africa trypanosome species by two serum trypanolytic factors, TLF-1 and
TLF-2, which exploit parasite nutrient scavenging pathways to take up and deliver lytic APOL1 protein to the
lysosome. A conformational change in the low pH environment of the lysosome releases APOL1 and exposes domains
that allow it to form anionic pores in the membrane, leading to osmotic imbalance and cell lysis. Two sub-species of T.
brucei have evolved speciﬁc mechanisms to overcome this innate resistance. In T. b. rhodesiense, expression of the SRA
gene, a truncated VSG, confers resistance to lysis by both TLF-1 and 2. Deletion of the VSG surface loops results,
ultimately, in its traﬃcking through the endocytic pathway, where it is able to bind APOL1 and prevent pore-forming
activity in the lysosome. In contrast, T. b. gambiense has evolved a complex, multi-component mechanism of HSR
involving reduction in the binding aﬃnity of TbgHpHbR for TLF-1, the expression of a T. b. gambiense speciﬁc
truncated VSG (TgsGP) which conceivably increases resistance of the lysosomal membrane to APOL1 disruption and
enhanced expression or activity of cysteine proteases (CP) that aid degradation of APOL1 within the endocytic pathway.
Recently, the discovery of certain APOL1 variants has suggested the evolution of counter measures to at least one of
these resistance mechanisms. APOL1 from a subset of primates of the cercopithecidae lineage are naturally resistant to
T. b. rhodesiense but not T. b. gambiense infection as a result of mutations in the SRA interacting domain that impair
SRA binding and restore APOL1 activity. In an example of convergent evolution, two haplotypes displaying similar
mutations, termed G1 and G2, have been identiﬁed in a number of human populations of African origin.
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By evolving a trypanolytic HDL, primates were
able to exploit both the trypanosomes’ high lipid
requirement necessary for fast turnover of the VSG
coat to maintain antigenic variation and the lack of a
haem production pathway in the parasite. However,
two sub-species of T. brucei have evolved their
own counters to overcome lysis by human serum
and APOL1. Both resistance mechanisms appear
to utilize a truncated VSG as an essential
component, SRA in T. b. rhodesiense and TgsGP in
T. b. gambiense. This highlights the evolutionary
potential that the huge VSG repertoire provides this
parasite. Although not covered during this review,
there are also two other potential serum resistance
mechanisms in T. brucei that do not utilize SRA or
TgsGP. In East sub-Saharan Africa, a small number
of human infective trypanosomes have been iden-
tiﬁed fromT. b rhodesiense foci that do not possess the
SRA gene (De Greef et al. 1989; Rifkin et al. 1994;
Enyaru et al. 2006). In Western sub-Saharan Africa,
sympatric with T. b gambiense, a further group of
human infective trypanosomes has been identiﬁed.
These are termed group 2 T. b. gambiense as they
do not ﬁt into the classical genetic proﬁles asso-
ciated with the much more prevalent group 1
T. b. gambiense (Gibson, 1986). Unlike group 1,
group 2T. b. gambiense do not possessTgsGP and the
resistance mechanism is variably expressed in a
manner reminiscent of T. b. rhodesiense. The resist-
ance mechanism does not appear to correlate with
changes in expression site, however (Capewell et al.
2011). How non-SRA T. b. rhodesiense and group 2
T. b. gambiense are able to overcome APOL1 remains
unclear, although it highlights the high potential
for T. brucei to quickly evolve to infect new hosts
and overcome innate immunity.
It is becoming apparent that the evolutionary
arms race between primates and T. brucei is con-
tinuing, with several human and primate populations
displaying resistance to both T. b. rhodesiense and
T. b gambiense. Understanding the complex co-
evolution that has occurred between trypanosomes
and primates may lead to prospective disease inter-
ventions. For example, inhibitors or antibodies that
target the essential proteins involved in each sub-
species’ resistance mechanism (SRA and TgsGP)
would render these parasites susceptible to normal
innate resistance and APOL1. An alternative ap-
proach is to identify APOL1 variants or other genes
present in trypanosome-resistant human and primate
populations that may serve as a universal therapy for
all African trypanosomes. Once identiﬁed, these
APOL1 variants must be targeted to trypanosomes
as APOL1 uptake when not bound to a facilitating
ligand is slow and ineﬃcient (Vanhamme et al.
2003; Baral et al. 2006). One proposed solution
involves the distribution of transgenic cows across
Africa that express either recombinant baboon
APOL1 (Thomson et al. 2009) or truncated human
APOL1 (Lecordier et al. 2009). Mice models
expressing these genes ectopically are unable to be
infected by either T. b. brucei or T. b. rhodesiense,
if expressed in concert with HPR and APOA1
(Thomson et al. 2009). An alternative proposed
delivery mechanism is the conjugation of variant
APOL1 to antibody fragments that target conserved
motifs on parasite VSGs (Baral et al. 2006). A caveat
to these proposed interventions is that the APOL1
variant used by each is not lytic to the most pre-
valent human infective trypanosome, T. b. gambiense
(Lecordier et al. 2009; Thomson et al. 2009). It
is possible that usage of such APOL1 variants
would select for increased incidence of human disease
by eradicating the competitor species such as
Trypanosoma congolense, Trypanosoma vivax or
Trypanosoma brucei. Nevertheless, it is clear that
understanding the co-evolution of primates and
African trypanosomes is a powerful tool in combating
human trypanosomiasis.
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